Marker Therapeutics, Inc.(MRKR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,768 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
MRKR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Marker Therapeutics, Inc. (MRKR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MRKR at 21.3/100 on a 32-signal composite quality model, placing it at rank #2,768 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of MRKR by reported 13-F value include NEA Management Company, Blue Owl Capital, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. MRKR trades on the Nasdaq exchange and files with the SEC under CIK 1094038. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MRKR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Marker Therapeutics, Inc. directly from SEC EDGAR. Marker Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 10 and 21 since 2026, currently 21.3 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-1.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-46.2% YoYNet Income
-13.3% YoYOperating Income
-15.9% YoYEPS (Diluted)
+33.6% YoYTotal Assets
-13.4% YoYOp. Cash Flow
-10.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.5M -46.2% | $6.6M +99.1% | $3.3M -5.8% | $3.5M | $0.00 -100.0% | $500.0K |
| Net Income | $-12.2M -13.3% | $-10.7M -30.3% | $-8.2M +72.5% | $-29.9M +28.5% | $-41.9M -45.9% | $-28.7M |
| Operating Income | $-12.9M -15.9% | $-11.1M +23.7% | $-14.6M +26.3% | $-19.8M +49.9% | $-39.5M -36.7% | $-28.9M |
| EPS (Diluted) | $-0.79 +33.6% | $-1.19 -26.6% | $-0.94 +73.7% | $-3.58 +34.6% | $-5.47 -796.7% | $-0.61 |
| Total Assets | $19.1M -13.4% | $22.0M +28.6% | $17.1M -50.2% | $34.4M -49.5% | $68.1M +49.4% | $45.6M |
| Operating Cash Flow | $-12.0M -10.1% | $-10.9M +33.6% | $-16.4M +39.0% | $-27.0M +1.1% | $-27.3M -36.2% | $-20.0M |
Get alerted when MRKR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Marker Therapeutics, Inc. including:
Top Institutional Holders of MRKR
NEA Management Company, LLC
$2.4M1,625,678 shBlue Owl Capital Holdings LP
$814.7K554,250 shVANGUARD CAPITAL MANAGEMENT LLC
$626.5K426,169 shAisling Capital Management LP
$478.3K325,370 shRENAISSANCE TECHNOLOGIES LLC
$366.7K249,423 shGEODE CAPITAL MANAGEMENT, LLC
$205.6K139,816 shOSAIC HOLDINGS, INC.
$165.6K112,649 shVANGUARD FIDUCIARY TRUST CO
$128.3K87,269 shLPL Financial LLC
$122.2K83,147 shConcurrent Investment Advisors, LLC
$99.9K67,963 sh
| Fund | Value | Shares |
|---|---|---|
| NEA Management Company, LLC | $2.4M | 1,625,678 |
| Blue Owl Capital Holdings LP | $814.7K | 554,250 |
| VANGUARD CAPITAL MANAGEMENT LLC | $626.5K | 426,169 |
| Aisling Capital Management LP | $478.3K | 325,370 |
| RENAISSANCE TECHNOLOGIES LLC | $366.7K | 249,423 |
| GEODE CAPITAL MANAGEMENT, LLC | $205.6K | 139,816 |
| OSAIC HOLDINGS, INC. | $165.6K | 112,649 |
| VANGUARD FIDUCIARY TRUST CO | $128.3K | 87,269 |
| LPL Financial LLC | $122.2K | 83,147 |
| Concurrent Investment Advisors, LLC | $99.9K | 67,963 |
More Healthcare Companies
View all Healthcare →Put MRKR on your watchlist
Track score changes the day Marker Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MRKR a good stock to buy?
13F Pro's AI-powered analysis of Marker Therapeutics, Inc. (MRKR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MRKR are available on the MRKR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MRKR is classified as a small company.
Which hedge funds own MRKR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MRKR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Marker Therapeutics, Inc.'s investment landscape.